Literature DB >> 12485118

The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.

Jin Il Kim1, Soo-Heon Park, Jae Kwang Kim, In Sik Chung, Kyu Won Chung, Hee Sik Sun.   

Abstract

BACKGROUND: The effects of nocturnal gastric acid breakthrough (NAB) on Helicobacter pylori eradication are still unknown in peptic ulcer patients. The purposes of this study were to compare the effect of lansoprazole 30 mg twice a day (bid) to lansoprazole 60 mg once a day (qd) on the prevalence of NAB, and to determine whether NAB affects the eradication of H. pylori in peptic ulcer patients.
METHODS: Experiments were carried out in 67 patients with H. pylori-positive peptic ulcers. They were randomized into two groups, one treated with a combination of lansoprazole 60 mg, clarithromycin 1.0 g, and amoxycillin 2.0 g once a day before breakfast (qd group), and the other, divided doses of the drugs were given before breakfast and dinner (bid group) for 2 weeks.
RESULTS: NAB occurred in 31 patients, 55.2% in qd group, and 39.5% in bid group (p =.226). H. pylori eradication was achieved in 61.3% in NAB positive group and 83.3% in NAB negative group (p =.055). The mean duration of NAB for H. pylori eradication group was 99.3 +/- 22.7 min, and 293.2 +/- 49.8 min for H. pylori persistence group (p <.05). The median intragastric pH of the H. pylori eradication and persistence group was 5.7 +/- 0.2 and 4.2 +/- 0.4, respectively (p <.05).
CONCLUSIONS: Neither the morning dose and the divided dose regimen of lansoprazole affected the intragastric acidity and occurrence of the NAB. NAB did not influence H. pylori eradication in peptic ulcer patients, but the duration of NAB and total intragastric median pH were found to influence the H. pylori eradication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12485118     DOI: 10.1046/j.1523-5378.2002.00105.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  6 in total

1.  The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.

Authors:  E A Marcus; N Inatomi; G T Nagami; G Sachs; D R Scott
Journal:  Aliment Pharmacol Ther       Date:  2012-09-25       Impact factor: 8.171

Review 2.  Potent Acid Suppression with PPIs and P-CABs: What's New?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

3.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

4.  Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Clin Transl Gastroenterol       Date:  2015-10-29       Impact factor: 4.488

Review 5.  Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.

Authors:  Tadayuki Oshima; Hiroto Miwa
Journal:  J Neurogastroenterol Motil       Date:  2018-07-30       Impact factor: 4.924

Review 6.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.